Obesity, Systemic Hypertension, and Pulmonary Hypertension: A Tale of Three Diseases.

[1]  S. Oparil,et al.  Obesity and Pulmonary Hypertension , 2018, Current Hypertension Reports.

[2]  C. Antoniades,et al.  Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets , 2017, British journal of pharmacology.

[3]  W. S. Ho,et al.  Pro‐contractile effects of perivascular fat in health and disease , 2017, British journal of pharmacology.

[4]  T. Guzik,et al.  Perivascular adipose tissue inflammation in vascular disease , 2017, British journal of pharmacology.

[5]  Alan D. Lopez,et al.  Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015 , 2017, Journal of the American College of Cardiology.

[6]  P. Whelton,et al.  Using Predicted Cardiovascular Disease Risk in Conjunction With Blood Pressure to Guide Antihypertensive Medication Treatment. , 2017, Journal of the American College of Cardiology.

[7]  W. Aronow.  Association of obesity with hypertension. , 2017, Annals of translational medicine.

[8]  N. Xia,et al.  The role of perivascular adipose tissue in obesity‐induced vascular dysfunction , 2016, British journal of pharmacology.

[9]  D. Prabhakaran,et al.  Obesity and its Relation With Diabetes and Hypertension: A Cross-Sectional Study Across 4 Geographical Regions. , 2016, Global heart.

[10]  D. Gee,et al.  Improvement in severe pulmonary hypertension in obese patients after laparoscopic gastric bypass or sleeve gastrectomy , 2016, Surgical Endoscopy.

[11]  U. Förstermann,et al.  Uncoupling of Endothelial Nitric Oxide Synthase in Perivascular Adipose Tissue of Diet-Induced Obese Mice , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[12]  Prasenjit Manna,et al.  Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. , 2015, Metabolic syndrome and related disorders.

[13]  A. Khera,et al.  The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. , 2014, Journal of the American College of Cardiology.

[14]  A. Arbor,et al.  Perivascular adipose tissue in vascular function and disease: a review of current research and animal models. , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[15]  M. Humbert,et al.  Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. , 2014, Circulation research.

[16]  J. van de Voorde,et al.  Perivascular adipose tissue, inflammation and vascular dysfunction in obesity. , 2014, Current vascular pharmacology.

[17]  R. Speich,et al.  Inflammatory cytokines in pulmonary hypertension , 2014, Respiratory Research.

[18]  Toru Satoh,et al.  Definitions and diagnosis of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[19]  M. Gil-Ortega,et al.  Mechanisms of Perivascular Adipose Tissue Dysfunction in Obesity , 2013, International journal of endocrinology.

[20]  S. Black,et al.  Reactive oxygen species in pulmonary vascular remodeling. , 2013, Comprehensive Physiology.

[21]  E. Finkelstein,et al.  The Effect of Weight Loss on Health, Productivity, and Medical Expenditures Among Overweight Employees , 2013, Medical care.

[22]  Jianping Ye.  Mechanisms of insulin resistance in obesity , 2013, Frontiers of Medicine.

[23]  A. Xu,et al.  Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction , 2013, Reviews in Endocrine and Metabolic Disorders.

[24]  S. Friedman,et al.  Obesity and Pulmonary Hypertension: A Review of Pathophysiologic Mechanisms , 2012, Journal of obesity.

[25]  P. Hassoun,et al.  Immune and inflammatory mechanisms in pulmonary arterial hypertension. , 2012, Progress in cardiovascular diseases.

[26]  G. D. De Keulenaer,et al.  Pulmonary hypertension and right heart failure in heart failure with preserved left ventricular ejection fraction: pathophysiology and natural history , 2012, Current opinion in cardiology.

[27]  M. Gladwin,et al.  Reactive oxygen and nitrogen species in pulmonary hypertension. , 2012, Free radical biology & medicine.

[28]  S. Provencher,et al.  Krüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension , 2011, Respiratory research.

[29]  R. Jörres,et al.  Pulmonary hypertension in obesity-hypoventilation syndrome. , 2011, Respiratory medicine.

[30]  O. Tawfik,et al.  Hypoxia-inducible factor-1 α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling , 2011, Respiratory research.

[31]  Hideki Tohda,et al.  New insights into galactose metabolism by Schizosaccharomyces pombe: isolation and characterization of a galactose-assimilating mutant. , 2011, Journal of bioscience and bioengineering.

[32]  R. Grunstein,et al.  Obesity hypoventilation syndrome: mechanisms and management. , 2011, American journal of respiratory and critical care medicine.

[33]  B. Mokhlesi.  Obesity hypoventilation syndrome: a state-of-the-art review. , 2010, Respiratory care.

[34]  R. Trembath,et al.  Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension , 2010, Circulation.

[35]  Scott D Covey,et al.  Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic beta-cell leptin signaling. , 2010, Endocrinology.

[36]  S. Corrao,et al.  Hypoadiponectinemia: A Link between Visceral Obesity and Metabolic Syndrome , 2010, Journal of nutrition and metabolism.

[37]  E. Mervaala,et al.  Periadventitial adipose tissue promotes endothelial dysfunction via oxidative stress in diet-induced obese C57Bl/6 mice. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[38]  C. Lavie,et al.  Obesity and hypertension, heart failure, and coronary heart disease-risk factor, paradox, and recommendations for weight loss. , 2009, The Ochsner journal.

[39]  R. Re.  Obesity-related hypertension. , 2009, The Ochsner journal.

[40]  C. D. Dela Cruz,et al.  Role of obesity in cardiomyopathy and pulmonary hypertension. , 2009, Clinics in chest medicine.

[41]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[42]  W. Kannel,et al.  Hazards of obesity--the Framingham experience. , 2009, Acta medica Scandinavica. Supplementum.

[43]  M. Humbert,et al.  Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. , 2009, The Journal of clinical investigation.

[44]  J. Orr,et al.  Sympathetic nervous system behavior in human obesity , 2009, Neuroscience & Biobehavioral Reviews.

[45]  S. Eddahibi,et al.  Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice , 2009, Respiratory research.

[46]  Jianping Ye.  Regulation of PPARgamma function by TNF-alpha. , 2008, Biochemical and biophysical research communications.

[47]  G. Bray,et al.  Weight loss and blood pressure control (Pro). , 2008, Hypertension.

[48]  R. Kreutz,et al.  Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. , 2008, The Journal of endocrinology.

[49]  R. Dankner,et al.  Insulin Resistance and Hyperinsulinemia , 2008, Diabetes Care.

[50]  T. Marwick,et al.  Obesity cardiomyopathy: diagnosis and therapeutic implications , 2007, Nature Clinical Practice Cardiovascular Medicine.

[51]  C. Glass,et al.  Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. , 2007, The Journal of clinical investigation.

[52]  Ahmad Y. Sheikh,et al.  Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator–Activated Receptor-&ggr; Activation , 2007 .

[53]  Y. Ho,et al.  Role of mitochondrial reactive oxygen species in hypoxia-dependent increase in intracellular calcium in pulmonary artery myocytes. , 2007, Free radical biology & medicine.

[54]  Jianping Ye.  Role of insulin in the pathogenesis of free fatty acid-induced insulin resistance in skeletal muscle. , 2007, Endocrine, metabolic & immune disorders drug targets.

[55]  G. Grassi.  Sympathetic Overdrive and Cardiovascular Risk in the Metabolic Syndrome , 2006, Hypertension Research.

[56]  O. Hamdy,et al.  Metabolic obesity: the paradox between visceral and subcutaneous fat. , 2006, Current diabetes reviews.

[57]  K. Clément,et al.  Review article: Is obesity an inflammatory illness? Role of low‐grade inflammation and macrophage infiltration in human white adipose tissue , 2006 .

[58]  M. Frid,et al.  Hypoxia-induced Pulmonary Vascular Remodeling Cellular and Molecular Mechanisms Reviews , 2022 .

[59]  James West,et al.  Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. , 2005, Chest.

[60]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[61]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[62]  E. Beller,et al.  Alterations of Left Ventricular Myocardial Characteristics Associated With Obesity , 2004, Circulation.

[63]  M. Cooper,et al.  Imatinib Attenuates Diabetes-Associated Atherosclerosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[64]  A. Rocchini.  Obesity and Blood Pressure Regulation , 2003 .

[65]  H. Dincer,et al.  Pathophysiology of pulmonary hypertension due to lung disease , 2003, Current opinion in pulmonary medicine.

[66]  M. White,et al.  IRS proteins and the common path to diabetes. , 2002, American journal of physiology. Endocrinology and metabolism.

[67]  Arthur E. Weyman,et al.  Clinical Correlates and Reference Intervals for Pulmonary Artery Systolic Pressure Among Echocardiographically Normal Subjects , 2001, Circulation.

[68]  S. Liu,et al.  Reactive oxygen species mediate cyclic strain-induced endothelin-1 gene expression via Ras/Raf/extracellular signal-regulated kinase pathway in endothelial cells. , 2001, Journal of molecular and cellular cardiology.

[69]  A. Chaouat,et al.  The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. , 2001, Chest.

[70]  B. Celli,et al.  The obesity hypoventilation syndrome can be treated with noninvasive mechanical ventilation. , 2001, Chest.

[71]  T. Young,et al.  Longitudinal study of moderate weight change and sleep-disordered breathing. , 2000, JAMA.

[72]  M. Schroll,et al.  Ageing, tumour necrosis factor‐alpha (TNF‐α) and atherosclerosis , 2000, Clinical and experimental immunology.

[73]  H Wedel,et al.  Differentiated long-term effects of intentional weight loss on diabetes and hypertension. , 2000, Hypertension.

[74]  X. Shen,et al.  Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. , 2000, Diabetes.

[75]  N. Clausell,et al.  Reciprocal induction of tumor necrosis factor‐α and interleukin‐β activity mediates fibronectin synthesis in coronary artery smooth muscle cells , 1995 .

[76]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[77]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[78]  N. Cook,et al.  The Effects of Nonpharmacologic Interventions on Blood Pressure of Persons With High Normal Levels: Results of the Trials of Hypertension Prevention, Phase I , 1992 .

[79]  S. Schwartz,et al.  Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. , 1992, The Journal of clinical investigation.

[80]  G. Vetrovec,et al.  Hemodynamic Dysfunction in Obesity Hypoventilation Syndrome and the Effects of Treatment with Surgically Induced Weight Loss , 1988, Annals of surgery.

[81]  Manning Feinleib,et al.  Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26‐year Follow‐up of Participants in the Framingham Heart Study , 1983, Circulation.

[82]  J. Dixon,et al.  Obesity Paradox in Hypertension: Is This Because Sympathetic Activation in Obesity-Hypertension Takes a Benign Form? , 2018, Hypertension.

[83]  J. Stamler,et al.  Weight and blood pressure. Findings in hypertension screening of 1 million Americans. , 1978, JAMA.